Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Basiliximab for Interstitial Pneumonia in CADM
NCT03192657Phase 2Unknown
- Sponsor
- Renji Hospital
- Start
- Jul 2017
- Primary completion
- Jun 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of basiliximab in interstitial pneumonia and dermatomyositis (DM) (2 arms), sponsored by Renji Hospital. Primary endpoint: Survival at 52 weeks. Status: unknown.
02
Drugs
basiliximab
03
Conditions
interstitial pneumoniadermatomyositis (DM)
Beyond the preview
Go deeper on NCT03192657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03192657.